Stockreport

Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... [Yahoo! Finance]

Lisata Therapeutics, Inc.  (LSTA) 
PDF Research and Development Expenses: $2.5 million for Q3 2024, down 24.8% from $3.4 million in Q3 2023. General and Administrative Expenses: $2.8 million for Q3 2024, a [Read more]